Zobrazeno 1 - 10
of 30
pro vyhledávání: ''
Autor:
Sachin K. Khiste, Mohammad Burhan Uddin, Ronald A. Hill, Sami Nazzal, Zhijun Liu, Xin Gu, Salman B. Hosain, Kartik R. Roy, Yong-Yu Liu
Publikováno v:
Mol Cancer Ther
Ceramide (Cer) is an active cellular sphingolipid that can induce apoptosis or proliferation-arrest of cancer cells. Nanoparticle-based delivery offers an effective approach for overcoming bioavailability and biopharmaceutics issues attributable to t
Autor:
Kyu-Tae Kim, Jeejin Im, Min Kyung Choi, Ky-Youb Nam, Jeong-Hyeok Yoon, Inki Kim, Sojung Park, June H-J. Han
Publikováno v:
Cancer Research. 81:1461-1461
Purpose: Development of the potent and selective checkpoint kinase 2 (CHK2) inhibitor to overcome limiting clinical utility of poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. Experimental Procedure: Preclinical evaluation of PHI-101 for cellular an
Autor:
Dan L. Sackett, Alex Kagansky, Susan E. Bates, Jung-Hyun Kim, Jane B. Trepel, Nicholas C.O. Lee, Hee-Sheung Lee, Yves Pommier, Natalay Kouprina, Vladimir Larionov
Publikováno v:
Cancer Research. 76:902-911
Whole chromosomal instability (CIN), manifested as unequal chromosome distribution during cell division, is a distinguishing feature of most cancer types. CIN is generally considered to drive tumorigenesis, but a threshold level exists whereby furthe
Autor:
Félix Bonilla, Cristina Peña, Belén Pérez-Sacristán, F. Granado-Lorencio, Gemma Domínguez, Beatriz Gil-Calderón, Jesús Espinosa Romero, Encarnación Donoso, Coral San Millán, Beatriz Soldevilla, Marta Compte, Paloma Martín
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Background]: The acquired resistance to chemotherapy represents the major limitation in the treatment of cancer. New strategies to solve this failure and improve patients' outcomes are necessary. The cancer preventive effect of β-cryptoxanthin has
Autor:
Soo-Hwan Lee, Seo-Yoon Jeong, Min Hee Hong, Seok-Young Kim, Hye Ryun Kim, Byoung Chul Cho, Jiyeon Yun, Chae Won Park
Publikováno v:
Cancer Research. 80:5198-5198
Background: 1st generation (erlotinib & gefitinib), 2nd generation (afatinib), and 3rd generation (osimertinib) EGFR TKIs have marked efficacy in patient with EGFR-mutant NSCLC. Unfortunately, patients who show T790M (-) mutation after treated with 1
Publikováno v:
Cancer Immunology Research. 8:A87-A87
Immunotherapy targeting the programmed cell death ligand 1/programmed cell death protein 1 (PD-L1/PD-1) pathway using antibodies is clinically effective in treating a spectrum of cancers. Acetaminophen (AAP) has shown antitumor and/or chemo-enhancing
Autor:
Naoya Fujita, Elizabeth L. Lockerman, Yuka Kobayashi, Ryohei Katayama, Luc Friboulet, Alice T. Shaw, Sumie Koike, Jeffrey A. Engelman
Publikováno v:
Clinical Cancer Research. 21:166-174
Purpose: ROS1 rearrangement leads to constitutive ROS1 activation with potent transforming activity. In an ongoing phase I trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib shows remarkable initial responses in patients with non–small cell
Autor:
Hajime Orita, Polina Sysa-Shah, Kathleen L. Gabrielson, Scott Pin, Rachel Bartock, Djahida Bedja, Xin Guo, An L. Moens, Yi Xu, Angela Hsieh, Venu Raman, Michael S. Wolin, Allison L. Tsao
Publikováno v:
Molecular Cancer Therapeutics. 13:1717-1728
Doxorubicin is a widely used chemotherapy for solid tumors and hematologic malignancies, but its use is limited due to cardiotoxicity. Geranylgeranylacetone (GGA), an antiulcer agent used in Japan for 30 years, has no significant adverse effects, and
Autor:
Noriko Gotoh, Arinobu Tojo, Susumu Kohno, Tatsunori Nishimura, Tomoyoshi Soga, Chiaki Takahashi, Asuka Nakata, Shin-ichi Horike
Publikováno v:
Cancer Research. 78:168-168
Tumor recurrence is attributable to cancer stem-like cells (CSCs), the metabolic mechanisms of which currently remain obscure. Here, we uncovered the critical role of folate-mediated one-carbon (1C) metabolism involving mitochondrial methylenetetrahy
Publikováno v:
Cancer Research. 78:5199-5199
Aim: Breast tumors of the basal-like, hormone receptor-negative subtype, remain an unmet clinical challenge, as patients exhibit the highest recurrence rate, the shortest time to recurrence and the worst overall survival rate due to a paucity of ther